Navigation Links
Medisafe 1 Technologies to Start the $1MM Stock Repurchase Program of 10MM Shares up to 10 Cents a Share
Date:2/14/2012

JERUSALEM, Israel, February 13, 2012 /PRNewswire/ --

Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company plans to start the implementation of the share buyback at the beginning of the forthcoming month of March 2012

Under the program approved by the BOD, Medisafe 1 Technologies is authorized to repurchase up to 10 million of its outstanding shares of common stock during the next 12 months at a price up to $0.10 per share on the open market or by conducting privately negotiated transactions depending on current market conditions and other factors.

"Medisafe 1 Technologies continues to progress in our efforts to bring further added value to our shareholders," said Jacob Elhadad, CEO of Medisafe 1 Technologies Corp. "The repurchase of shares will enable us to acquire additional technologies that augment our existing commercial product line and we will updating our shareholders in the forthcoming weeks of new and exciting news in regards to further acquisitions."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact: Jacob Elhadad CEO +972-524440000 Jacob.elhadad10@gmail.com



'/>"/>
SOURCE Medisafe 1 Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
2. Medisafe 1 Technologies Announces 1-5 Stock Dividend
3. Spherix to Present at the LHA Life Sciences & Medical Technologies Virtual Conference on February 16
4. BioStorage Technologies to Host Global Sample Management Workshop at Partnerships in Clinical Trials
5. UV Flu Technologies Continues Aggressive Program to Pay off Convertible Debt
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference
8. Cell Therapy - Technologies, Markets and Companies
9. Life Technologies to Present at Upcoming Investment Conferences in February
10. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
11. Life Technologies Announces Redemption of 1.5% Convertible Senior Notes Due 2024
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2019)... ... June 12, 2019 , ... Leak Detection Associates (LDA), ... Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries, is excited to announce that ... grant exclusive rights for Zillion to represent LDA in all of China. ...
(Date:6/11/2019)... Calif. (PRWEB) , ... June 10, 2019 , ... ... today announced IOPP will add 80 of its scientific journals to DeepDyve’s rental ... physics-related content to DeepDyve’s continually expanding library of more than 20 million articles, ...
(Date:6/11/2019)... N.C. (PRWEB) , ... June 11, 2019 , ... ... extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to incorporate ... cloning ability. In a test on mice, MSC-EVs also increased the cells’ ability ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... providing proprietary interest to our methodology, processes, and diagnostic techniques. The patent ... extends Somnology’s IP rights including our proprietary sleep scoring methodology. The approval ...
Breaking Biology Technology:
(Date:6/1/2019)... ... 31, 2019 , ... The University of Vermont Health Network ... $6M Series B Financing Round. , “With the commitment from the UVM ... financial and business resources to bear as we advance our biopharmaceutical products to ...
(Date:5/31/2019)... (PRWEB) , ... May 30, 2019 , ... ... genetics testing company, and Mayo Clinic, have documented significant differences in the prevalence ... racial and ethnic populations compared to non-Hispanic White women. Results will be presented ...
(Date:5/31/2019)... ... May 30, 2019 , ... Enso Discoveries Chief Executive Officer, ... Military Appreciation Month, as a way to express his gratitude and respect for those ... he founded — Enso Discoveries — presented a check for $1,000 to ...
Breaking Biology News(10 mins):